EMPLOYMENT AGREEMENTEmployment Agreement • September 25th, 2017 • Deciphera Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”) is made as of the 25th day of September, 2017, by and between Oliver Rosen, M.D. (the “Executive”) and Deciphera Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”; the Executive and the Company are collectively referred to as the “Parties”). This Agreement shall be effective as of the closing of the first underwritten public offering of the equity securities of Deciphera Pharmaceuticals, Inc. (“Parent”) pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
REORGANIZATION AGREEMENT AND PLAN OF MERGERReorganization Agreement and Plan of Merger • September 25th, 2017 • Deciphera Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS REORGANIZATION AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of September , 2017, by and among Deciphera Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Parent”), DP Mergersub, LLC, a Delaware limited liability company and a wholly owned Subsidiary of the Parent (“Merger Sub”), the members of the Company (the “Members”), including the Blockers, and the parties set forth on Exhibit E (the “Blocker Holders”). The Company, Parent, Merger Sub, Members, Blockers and Blocker Holders are sometimes collectively referred to herein as the “Parties” and individually as a “Party” and the Members, Blockers, and Blocker Holders are collectively referred to herein as the “Holders.” Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in Section 8.
DECIPHERA PHARMACEUTICALS, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 25th, 2017 • Deciphera Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of September, 2017, by and among Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. Capitalized terms used herein without definition shall, unless otherwise indicated, have the meaning specified in the Company’s Certificate of Incorporation, as may be amended or restated from time to time.
